Table 3 The association between TMOD1 and PTCSC2 polymorphisms and the risk of thyroid carcinoma
SNP-ID | Model | Genotype | Case (%) | Control (%) | Adjusted by age and sex | |
|---|---|---|---|---|---|---|
OR (95% CI) | p | |||||
rs10982622 | Codominant | AG | 196 (38.4%) | 231 (45.7%) | 0.74 (0.57–0.96) | 0.025 |
GG | 245 (48.0%) | 214 (42.3%)) | 1.00 | |||
rs925489 | Allele | T | 891 (87.4%) | 918 (90.9%) | 1 | |
C | 129 (12.6%) | 92 (9.1%) | 1.45 (1.09–1.92) | 0.011 | ||
Codominant | CT | 117 (22.9%) | 88 (17.4%) | 1.43 (1.05–1.95) | 0.024 | |
TT | 387 (75.9%) | 415 (82.2%) | 1.00 | |||
Dominant | CC.CT | 123 (24.1%) | 90 (17.8%) | 1.47 (1.08–1.99) | 0.014 | |
TT | 387 (75.9%) | 415 (82.2%) | 1.00 | |||
Additive | / | / | / | 1.47 (1.10–1.97) | 0.009 | |
rs965513 | Allele | G | 893 (87.7%) | 918 (90.9%) | 1.00 | |
A | 125 (12.3%) | 92 (9.1%) | 1.40 (1.05–1.86) | 0.021 | ||
Codominant | AG | 113 (22.2%) | 88 (17.4%) | 1.37 (1.00-1.87) | 0.048 | |
GG | 390 (76.6%) | 415 (82.2%) | 1.00 | |||
Dominant | AA.AG | 119 (23.4%) | 90 (17.8%) | 1.41 (1.04–1.92) | 0.028 | |
GG | 390 (76.6%) | 415 (82.2%) | 1.00 | |||
Additive | / | / | / | 1.42 (1.06–1.90) | 0.019 | |